The percent change from baseline in T1 hypointense lesion volume between the fingolimod and IFN β-1a treatment groups was not significant at EOS ( table 4 ) and consistently did not reach statistical significance throughout the study.
← all excerpts
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> study.
1
—
—